BioSpace News Archive

The global c-reactive protein testing market size is expected to be worth around US$ 10.6 billion by 2030, according to a new report by Vision Research Reports.

Cytokinetics, Incorporated announced that on November 30, 2022 it granted stock options to purchase an aggregate of 146,100 shares of common stock to 14 new employees, whose employment commenced in November 2022, as a material inducement to their employment.

Akebia Therapeutics, Inc., a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted one newly-hired employee options to purchase an aggregate of 3,000 shares of Akebia’s common stock on November 30, 2022, as an inducement material to such employee entering into employment with Akebia.

Molecular Templates, Inc. announced that they will present a poster on interim clinical results for the MT-5111 program at the San Antonio Breast Cancer Symposium which will take place December 6 – December 10, 2022 at the Henry B. Gonzalez Convention Center in San Antonio, TX.

Amedisys, Inc., a leading provider of home health, hospice, personal care and high-acuity care, announced that Paul B. Kusserow, Chairman and Chief Executive Officer and Scott Ginn, Chief Operating Officer, will present at the Bank of American Securities Home Care Conference on Tuesday, December 6 at 9 a.m. ET.

Adicet Bio, Inc. today announced that the Company will host a webcast presentation on Sunday, December 11, 2022 at 9:00 a.m. EST to discuss the most recent data-cut from its ongoing Phase 1 study evaluating the safety and tolerability of ADI-001 for the potential treatment of relapsed or refractory B-cell NHL.

Vaxxinity, Inc. (Nasdaq: VAXX) announced today that its next generation UB-612 COVID-19 vaccine, when administered as a single heterologous booster dose, elicited strong neutralizing antibodies against SARS-CoV-2 when compared head-to-head to three globally authorized platform vaccines administered as homologous boosters, confirming success in meeting the primary and key secondary immunogenicity endpoints of its pivotal global Phase 3 trial.

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announced that Marc Voigt, CEO, will participate in The JMP Securities Hematology and Oncology Summit, a virtual investor event to be held from December 6-7, 2022.

IVERIC bio, Inc. reported that on December 1, 2022, the Company granted equity-based awards pursuant to the Company’s 2019 Inducement Stock Incentive Plan to nine newly-hired, non-executive employees.

The global sacroiliac joint fusion market size is expected to be worth around US$ 761.45 million by 2030, according to a new report by Vision Research Reports.